Fate Therapeutics Q4 EPS $(0.27) Misses $(0.26) Estimate, Sales $1.369M Beat $1.186M Estimate
Benzinga Newsdesk 8 months ago
EarningsEarnings BeatsEarnings MissesNews
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 38.64 percent increase over losses of $(0.44) per share
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 38.64 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $1.369 million which beat the analyst consensus estimate of $1.186 million by 15.43 percent. This is a 26.40 percent decrease over sales of $1.860 million the same period last year.